Article Text

Download PDFPDF
Variation in physician-directed immunohistochemistry screening among women with endometrial cancer
  1. Chelsea Virginia Salyer1,
  2. Makdine Dontsi2,
  3. Mary Anne Armstrong2,
  4. Scott Lentz3,
  5. Elizabeth Hoodfar4 and
  6. Bethan Powell2,5
  1. 1 Kaiser Permanente Department of Obstetrics & Gynecology, Oakland, CA, United States
  2. 2 Kaiser Permanente Division of Research, Oakland, California, USA
  3. 3 Kaiser Permanente Southern California Gynecologic Oncology Program, Los Angeles, California, USA
  4. 4 Kaiser Permanente Northern California Regional Genetics Program, Roseville, California, USA
  5. 5 Kaiser Permanente Northern California Gynecologic Oncology Program, San Francisco, California, USA
  1. Correspondence to Dr Bethan Powell, Gynecologic Oncology, Kaiser Permanente Northern California, San Francisco, CA 94115, USA; bethan.powell{at}kp.org

Abstract

Objective Immunohistochemistry screening is a reliable method for identifying women with endometrial cancer who are at risk for Lynch syndrome, but clinical workflows used to implement immunohistochemistry screening protocols can vary by institution. The goal of this study was to investigate variation in performance of immunohistochemistry screening when a physician order is required.

Methods Retrospective study from an integrated healthcare system with a risk-based immunohistochemistry screening policy for Lynch syndrome from January 2015 to December 2016. Immunohistochemistry screening was indicated for all women with endometrial cancer aged <60 years and women with endometrial cancer aged ≥60 years who had a personal/family history suggestive of Lynch syndrome. However, a physician order was needed to have immunohistochemistry screening performed on the tumor specimen as our health system did not have reflex screening in the clinical workflow. Demographics and tumor characteristics were reviewed, and patients were stratified by immunohistochemistry screening status. Multivariable regression was performed to identify factors associated with immunohistochemistry performance and reported as odds ratios (ORs) with 95% confidence intervals (CIs).

Results There were 1399 eligible patients in the study. With a required physician order, immunohistochemistry screening rates (20% overall, 34% aged <60 years) were significantly lower than previous reports (36% overall, 90% aged <60 years, p≤0.0001 for both comparisons). Significant factors associated with immunohistochemistry screening performance identified by multivariable analysis included age, race, body mass index, personal/family cancer history, diabetes, endometrioid histology, and tumor grade. Asian women were most likely to have immunohistochemistry screening (OR 1.58, 95% CI 1.07 to 2.34) whereas black women were least likely (OR 0.43, 95% CI 0.22 to 0.91).

Conclusions Immunohistochemistry screening rates in women with endometrial cancer were lower in our health system compared with prior reports in the literature, and there were variations in screening performance according to patient age, race, and body mass index. Requiring a physician order for immunohistochemistry screening likely creates a barrier in screening uptake, therefore automated immunohistochemistry screening is recommended.

  • Lynch syndrome II
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors CS: conceptualization and design, data collection, data interpretation, writing—original draft, writing—review and editing. MD: conceptualization, data analysis and data interpretation, writing—review and editing. MAA: conceptualization and design, data analysis and data interpretation, writing—review and editing. SL: conceptualization, data interpretation, writing—review and editing. EH: conceptualization, data interpretation, writing—review and editing. CBP: funding acquisition, conceptualization and design, data collection, data interpretation, writing—original draft, writing—review and editing.

  • Funding This study was supported by a grant from the Kaiser Permanente Northern California Community Benefit Program (Principal Investigator: CBP).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All data relevant to the study are included in the article.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.